1 published article · Updated continuously
8 trials tracked for Seborrheic keratosis: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 14 citations.
Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical trials evaluating the A-101 solution for seborrheic keratosis demonstrate various measures of efficacy. In a Phase 2 study, the mean percentage of target lesions judged to be clear (PLA=0) at Visit 8 reached 3.72, 49.5, and 57.88 across different treatment arms 5.
Additional Phase 3 trials involving A-101 solution reported a 56% clearance rate for lesions 3. In a separate Phase 2 trial, the percentage of PLA responders with target lesions judged clear at Visit 8 was 22, 18, and 1 across the respective arms (p<0.0001), with corresponding mean changes from baseline in PLA scores of -1.7, -1.4, and -0.1 (p<0.0001) 7.
A Phase 4 study assessing A-101 Topical Solution reported a correlation of 0.318 between the Physician Lesion Assessment (PLA) score and patient satisfaction 1. Multiple Phase 3 trials were conducted to evaluate the A-101 solution [2, 4].
AI synthesis of 6 cited trials, updated Sep 9, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
